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A B S T R A C T
The Global Meningococcal Initiative (GMI) is a global expert group, including scientists, clinicians and
public health officials from a wide range of specialities. The goal of the GMI is to prevent meningococ-
cal disease worldwide through education, research, and co-operation. The Chinese GMI roundtable meeting
was held in June 2017. The GMI met with local experts to gain insight into the meningococcal disease
burden in China and current prevention and vaccination strategies in place. China experienced five epi-
demics of serogroup A meningococcal disease (MenA) between 1938 and 1977, with peak incidence of
403/100,000 recorded in 1967. MenA incidence rates have significantly declined following the universal
introduction of the MenA polysaccharide vaccine in China in the 1980s. Further, surveillance data indi-
cates changing meningococcal epidemiology in China with the emergence of new clones of serogroup B
from serogroup C clonal complex (cc) 4821 due to capsular switching, and the international spread of
serogroup W cc11. The importance of carriage and herd protection for controlling meningococcal disease
was highlighted with the view to introduce conjugate vaccines and serogroup B vaccines into the na-
tional immunization schedule. Improved disease surveillance and standardized laboratory techniques across
and within provinces will ensure optimal epidemiological monitoring.
Crown Copyright © 2018 Published by Elsevier Ltd on behalf of The British Infection Association. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Introduction
Neisseria meningitidis (Nm) is an obligate human pathogen, and
is the cause of invasive meningococcal disease (MD).1 Nm strains
can be classified into 12 serogroups (A, B, C, E, H, I, K, L, W, X, Y, Z)
based on the immunochemistry of its capsular polysaccharides. Six
serogroups (A, B, C, W, X and Y) account for the majority of all cases
of MD worldwide.2,3 The remaining serogroups (E, H, I, J, L and Z)
are usually only found in carriage, but can cause invasive disease
in immuno-compromised individuals, such as patients with com-
plement deficiencies.4
The Global Meningococcal Initiative (GMI) was established in
2009 and is a multidisciplinary group of over 50 scientists and cli-
nicians dedicated to the prevention of MD worldwide through
education, research and international co-operation. A number of
global and regional GMI meetings have been held since its inception,5
including this regional meeting in Chengdu, Sichuan province, China
in June 2017. Experts were not available to attend the GMI meeting
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from all 34 provinces across China; however, attendees included
several representatives from the Chinese Center for Disease Control
and Prevention (CDC; Beijing, Shanghai, Guangdong and Liaon-
ing), as well as scientists and clinicians from hospital-based
departments relating to infectious disease. Members from Public
Health England (United Kingdom [UK]), Institute Pasteur (France)
and the World Health Organization also attended to share their ex-
periences and the lessons learned from their vaccination and
outbreak programs.
The specific meeting objectives were to: (i) review the global in-
cidence and epidemiology of MD, including China; (ii) provide an
update on MD surveillance, prevention and control strategies from
both a provincial (Liaoning province and Guangdong province) and
national perspective; (iii) discuss the issues faced regarding MD and
bacterial meningitis (BM) surveillance, prevention and control strat-
egies with a focus on current barriers to implementation; (iv)
highlight the importance of conjugate vaccines and their impact on
the prevention of MD; and (v) discuss key learning points from im-
munization programs used worldwide in outbreak control and
preparedness. This paper summarizes the key discussion points and
subsequent recommendations from the meeting to help inform
global and regional recommendations for MD prevention.
Review of the global incidence and epidemiology of meningococcal
disease
The global distribution and incidence of MD varies from 0.11 to
2 cases per 100,000 population in Europe and North America,6,7 to
more than 100 cases per 100,000 population in the “meningitis belt”
of sub-Saharan Africa.8 The incidence of MD in Africa subse-
quently fell to 0.02 cases per 100,000 between 2011 and 2013 after
the introduction of the MenAfriVac® vaccine in 2010.8 In China, the
MD incidence rate is 0.047 cases per 100,000 population based on
data from 2006 to 2014 from the National Notifiable Disease Re-
porting System (NNDRS).9 However, recent subnational estimates
indicate an incidence rate of 1.84 cases per 100,000 population, sug-
gesting that the overall incidence rate for China is underestimated.10
Historically, China has experienced five epidemics of MD between
1938 and 1977.10,11 The peak incidence of MD was recorded in 1967
with 403 cases per 100,000 population, >3,040,000 recorded cases
and >160,000 deaths with a case fatality rate of approximately 5.5%.
Following the universal use of serogroup A MD (MenA) polysac-
charide vaccines in China in the 1980s and the introduction of MenA
polysaccharide vaccines in to the Expanded Programme for Immu-
nization (EPI) in China in 2008, the reported incidence of MD has
steadily declined to <0.52 cases per 100,000 population in 200912;
this decline has been particularly evident in the last five years owing
to an increasing vaccination coverage rate.
The incidence and prevalence of Nm serogroups continually varies
both geographically and temporally.10,13 Meningococcal epidemi-
ology suggests an increased incidence and prevalence of MD during
mass gatherings that involve migration and travel.14–16 Further, Nm
is susceptible to frequent genetic transformations due to natural hor-
izontal DNA exchanges between isolates.17
Currently, serogroup B MD (MenB) is the most prevalent globally.7
Multilocus sequence typing (MLST) of MenB isolates worldwide re-
vealed three major hyperinvasive clonal complexes (ccs) (sequence
type [ST]-32, ST-41/44 and ST-269) in Europe and the United States
of America (USA).18 Further, cc ST-11 previously observed among
serogroup C MD (MenC) and serogroup W MD (MenW) isolates has
since occurred in cases of MenB due to capsular switching.19,20 MenA
is the most common serogroup involved in MD pandemics and is
predominantly found in China and Africa.21 The last major expan-
sion of MenA observed in Africa and China was in the 1980s;
however, both nations experienced the same clonal replacement of
ST-5 with ST-7 in the 1990s.21,22 Serogroup X MD (MenX) emerged
in Africa in the 1990s, reaching epidemic levels in Niger in 2006.23
Cases of MenX isolates related to those responsible for meningo-
coccal outbreaks in Niger, Togo and Burkina Faso have recently been
recorded in Northern Italy among African and Bangladeshi mi-
grants living in refugee camps.14 MenW has been known since the
1980s; however, its emergence as an epidemic serogroup was re-
ported in 2000, in Hajj pilgrims returning to France and the UK.24
Whole genome sequencing (WGS) data suggest a multifocal emer-
gence of MenW isolates worldwide with the identification of two
sub-lineages; one in individuals traveling to Mecca and in local South
African residents, and the other in South America and the UK.15 Re-
cently emerging MenC strains in sub-Saharan Africa were different
isolates from those previously observed in 1980 and 2012. Follow-
ing genomic analysis of the new clone of MenC identified in men
who have sex with men (MSM), the strain was found to have evolved
to acquire the capacity to spread via sexual transmission, as well
as by respiratory droplets.25
In China, the earliest serogroup A Nm was isolated in the 1950s
(Fig. 1) and almost all isolated MenA strains since have been iden-
tified as cc1 or cc5. ST-5 and -7 are two major classifications of cc5
MenA, and ST-3 is a major classification of cc1 MenA. ST-5 (cc5
MenA) first emerged in the 1950s, however was gradually re-
placed by ST-3 (cc1 MenA) in the 1960s. Since 1980, MenA caused
by ST-3 has continuously declined, and ST-7 has since been the pre-
dominant clone of MenA. In China, the incidence of MenB is
increasing. Prior to 2000, invasive cc11, cc32 and cc8 strains were
occasionally identified; however, more recently, MenB cc4821 has
emerged. From 2003 to 2005, several MD epidemics occurred in the
Anhui province, China; the MenC isolates attributed to such out-
breaks were identified as the unique cc4821.26 Genomic analysis
Fig. 1. Molecular epidemiology of Neisseria meningitidis in China.
430 J. Li et al. / Journal of Infection 76 (2018) 429–437
determined a high probability that cc4821 MenB originated from
cc4821 MenC.27 The first case of MenW in China was recorded in
the Fujian province of Southeast China. Subsequently, MenW has
been recorded in several provinces across China with the majority
of isolates identified as belonging to the cc11 lineage that devel-
oped in South Africa and caused a recent MD outbreak following
the World Scout Jamboree in Japan in 2015.16,28,29 A single case of
ST-7 MenX was reported in China in 2015 and is believed to have
originated from ST-7 MenA by horizontal exchange of capsule bio-
synthesis genes.30–32 In 2016, a single case of serogroup Y Nm was
isolated from a patient in Tianjin; however, there have since been
no recorded serogroup Y MD (MenY) cases indigenous to China.32
Further, capsular switching has been described among menin-
gococcal serogroups A and C,33 serogroups A and X34 and serogroups
B and C.27,35 Following the sequencing of whole capsular and sur-
rounding genes and the identification of potential recombination
sites, it was determined that ST-7 MenC was likely to have evolved
from ST-7 MenA as a result of capsular gene rearrangement.33 In ad-
dition, ST-7 MenX was determined as likely to have originated from
ST-7 MenA via recombination leading to capsular switching fol-
lowing the identification of probable recombination regions during
genomic analysis, however only one case was recorded.34
The continued epidemiological and sentinel surveillance of MD
provides an overview of trends and prevalence of different menin-
gococcal serogroups and is important in order to inform vaccination
and disease planning.
Surveillance and prevention strategies of meningococcal disease in
China
In China, multiple centers for immunization planning and the
control and prevention of infectious disease have been estab-
lished in order to conduct regular MD surveillance. Disease
surveillance and treatment are initiated if there are ≥3 identified
cases of MD within 14 days in any given township, or ≥5 cases re-
corded within one month in a county. As MD is one of 38 statutorily
notifiable diseases in China, all cases, including suspected cases, must
be reported to the CDC via the NNDRS. Indeed, epidemiological sur-
veillance includes acute BM case findings, reported case surveys,
outbreak surveys, and cerebrospinal fluid (CSF), blood and pete-
chial specimen collections. Although available methods may differ
between cities and provinces, laboratory tests may include isolate
and serology testing, drug resistance testing, MD antibody inves-
tigations, and Nm carriage surveillance in healthy populations.
However, the disease surveillance system is not sufficiently sensi-
tive to recognize all cases of MD, as not all hospitals have the capacity
to diagnose MD via laboratory tests. Therefore, it is likely that the
disease burden of Nm and probable BM in China is higher than es-
timated. In order to improve the validity of disease burden data,
technological advances with respect to pathogen detection are
needed.
Surveillance data from Chinese provinces indicate that there
remains a higher prevalence of MD in the Anhui, Xinjiang and
Guizhou provinces compared with national levels among children
and adolescents.36 In China an increase in MD prevalence among
adolescents may, in part, be due to university living conditions such
as co-habitation in dormitories. During 2004–2006, an outbreak of
MenC in the Anhui province resulted in >500 recorded cases with
a mortality rate of 7.8%. MenC accounted for the majority of MD cases
in China from 2008 to 2010, and was recorded in >80% of prov-
inces; during this time, MenB occurred relatively infrequently.37 From
2011 onwards, the proportion of MenC cases began to decline and
MenB to rise, with the majority of recorded cases in children <1 year.
In 2015, MD caused by MenY began to emerge. While there are many
recorded cases of serogroups A, B and C across China,38 MenX has
only been identified in MD patients in two provinces.30,34
Currently, 12 vaccines are freely available via the Chinese EPI for
the control of 15 infectious diseases, including MD and hepatitis
A. The MenA polysaccharide vaccine and the MenA plus MenC poly-
saccharide vaccine are available via the routine immunization
program at no extra cost to individuals. There is a wider range of
MD conjugate vaccines available in China, but the cost must be
covered by the individual. Currently available vaccines include: the
MenA plus MenC polysaccharide-protein conjugate; serogroup ACWY
meningococcal polysaccharide vaccine; and MenA, MenC and
Haemophilus influenzae type b (Hib) conjugate vaccines.
The routine MD immunization schedule for children in China
(Fig. 2) is as follows: children aged 6–18 months are given two doses
Fig. 2. Routine immunization schedule in China.
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of the MenA polysaccharide vaccine separated by three months, and
subsequently receive a single dose of the MenA plus MenC poly-
saccharide vaccine at ages 3 and 6 years. If the child has not received
the MenA polysaccharide vaccine between the ages of 2 and 4 years,
they will receive the MenA plus MenC polysaccharide vaccine, with
an interval of 3 years between the initial immunization and booster
vaccine.
Liaoning province
Liaoning province is located in the northeast of China, with a pop-
ulation of approximately 43 million people.39 Currently, the incidence
rate of MD is <1 case per 100,000 population, with the majority of
cases recorded during the springtime, and in the cities of Shenyang
and Dalian, from 2004 to 2016. MD mainly affects individuals aged
0–15 years, while children, students and farmers (defined as la-
borers that travel from rural areas into cities for work) are the three
main groups affected.
Surveillance data has demonstrated that serogroup A repre-
sents the highest number of meningococcal strains isolated from
patient cases and close contacts of individuals with MD. From 2004
to 2016, serogroup A accounted for 75% of patient cases among 20
isolated strains of Nm, while serogroups B and C were detected less
frequently. Further, 52 strains of Nm were observed among 922 close
contacts of individuals with MD sampled by pharyngeal swab de-
tection from 2004 to 2016, representing a 5.64% detection rate.
Serogroup A accounted for 69.23% of close contacts, and serogroups
B, C, W and Y were detected less often. In healthy carriers of me-
ningococci, serogroup B and non-serogroupable represents the
majority of recorded strains.
In accordance with national policy, the MenA polysaccharide
vaccine and the MenA plus MenC polysaccharide vaccine have been
freely available in Liaoning since 1985 and 2008, respectively, and
conjugate vaccines are available only for private purchase. Vac-
cines are administered via the EPI as previously described (Fig. 2).
Due to the expansion of the national immunization program, there
is a continuing decrease in the incidence of MD in Liaoning; however,
meningococcal vaccines for serogroups B, X, W and Y are not li-
censed, or incorporated into the EPI schedule, in China. Therefore,
continued disease surveillance and close monitoring, as well as en-
suring high rates of immunization coverage, are important for
continuing disease control.
Guangdong province
Guangdong is a province located on the South China Sea coast.
Guangdong has a permanent population of approximately
108,490,000 accounting for 7.9% of the total population of China.40
The peak prevalence of MD cases in Guangdong was reported in 1967
with 705.04 cases per 100,000 population (Fig. 3). In 2016, Gua-
ngdong had an MD incidence rate of 0.0037 cases per 100,000
persons, with a case fatality rate of 25% (i.e. one reported death).
From 2012 to 2016, 32 sporadic cases of MD and four fatalities
were reported in 11 cities across the Guangdong province. MenB
accounted for the majority of reported isolates. Although MD
cases were reported year round, disease incidence was highest in
the winter and spring with 25% of cases reported in January.
Patients’ age ranged from 10 days to 56 years: 46.9% of patients
were <6 months old and not yet eligible for immunization, and
68.8% of patients were <14 years old. The remainder of patients
were adults in whom meningococcal vaccinations were not rou-
tinely offered.
The MenA polysaccharide vaccine was introduced into the Gua-
ngdong province immunization policy from 2000. In 2008, the MenA
polysaccharide vaccine and the MenA plus MenC polysaccharide
vaccine were made freely available to patients via the EPI. The MenA
plus MenC conjugate vaccine and the serogroup ACWY meningo-
coccal polysaccharide vaccine became available for private purchase
in 2007 and 2008, respectively. Meningococcal vaccines in the Gua-
ngdong province are administered via the Chinese immunization
schedule for children (Fig. 2).
MD prevention measures in Guangdong province include im-
munization, surveillance, raising awareness among the general public,
and physician training, along with routine reporting, sentinel sur-
veillance and the management of epidemics. From 2005 to 2013,
sentinel surveillance was carried out in Guangdong to determine
Fig. 3. The incidence of MD in the Guangdong province between 1950 and 2016.
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meningococcal carriage rates, antibody prevalence and antibiotic
resistance among healthy participants across several age groups (<1,
1–2, 3–4, 5–6, 7–14, 15–19 and ≥20 years). Data demonstrated that
positive and protection rates of antibody levels against MenC were
low in children <1 year, yet increased in children aged ≥3 years.41
For the prophylaxis and treatment of MD, resistance tests are con-
ducted annually to determine the effectiveness of antibiotics;
however, there is a need for national guidelines advising on which
antibiotics should be used in control of the disease. Again, contin-
ued disease surveillance alongside high rates of immunization
coverage are imperative for the continued control and future pre-
vention of MD.
Overall, the prevalence rates of MD in China continue to de-
crease annually due to the increasing coverage of vaccination and
immunization. In order to decrease the incidence of MD further,
China may benefit from the integration of conjugate vaccines in to
the EPI and from increased immunization among high-risk groups
and target populations in specific areas known to suffer from fre-
quent meningococcal epidemics.
Addressing surveillance/diagnostic challenges of meningococcal
disease in China
Microbiological laboratory analyses play a critical role in the di-
agnosis of MD and the identification of causative strains of the
disease. Laboratory analyses help in the detection of outbreaks: both
in establishing the local or regional spread of infective strains and
subsequent guidance of appropriate therapy, and in the identifica-
tion of emerging pathogenic or virulent variants of the disease.
Common laboratory techniques used in the isolation, identifica-
tion and characterization of Nm include both blood and CSF cultures,
serogrouping (using antisera and polymerase chain reaction [PCR])
and the creation of stock for future analysis. In China, the main
methods used for confirming a diagnosis of Nm are by blood culture,
CSF culture and real-time PCR (rtPCR).
Shanghai is a region of China with a traditionally high inci-
dence of MD due to Nm. In Shanghai, laboratory methodologies
currently available for confirming a diagnosis of Nm are blood cul-
tures, CSF, latex agglutination and rtPCR. Isolates collected from
patients with Nm, close contacts of individuals with Nm and car-
riers of Nm can undergo serogrouping, MLST and pulse-field gel
electrophoresis (PFGE) to investigate serogroup prevalence, cc prev-
alence and genetic relationships. Antibiogram and gyrA sequencing
were used to investigate the changes in Nm quinolone susceptibil-
ity from 1965 to 2013 that were associated with the introduction
and expanding use of quinolones in Shanghai. Quinolones have been
widely used in China since the end of the 1980s, and have been rec-
ommended for Nm prophylaxis since 2005. The use of antibiogram
and gyrA sequencing demonstrated a high prevalence of Nm
quinolone non-susceptibility in Shanghai, which was associated with
hyper-virulent MD lineages cc4821 and cc5 in turn due to two
quinolone-resistant clones; Chinacc4821-R1-C/B and Chinacc5-R14-A.42 In
Shanghai, the average incidence rate of MD decreased from 43 cases
per 100,000 population between 1965 and 1985, to 0.08 cases per
100,000 population between 2005 and 2013. Conversely, the case
fatality rate has increased from 3% between 1961 and 1970 to 10%
between 2001 and 2013.42
When culture results are negative, rtPCR can be used in the di-
agnosis of Nm and identification of causative serogroups.43 For further
strain characterization beyond the serogroup, nested MLST can then
be used to identify the strain cc and ST.44
Laboratory methods in Shanghai are very robust and ongoing
methods for comprehensive MD strain characterization through-
out China involve the continuous analysis of WGS data, including
characterizing the aforementioned quinolone-resistant clones.
Pediatric bacterial meningitis in China
Globally, BM is a major cause of illness among infants and chil-
dren and is among the top ten causes of death in children <5 years.45
Between 2007 and 2016, Beijing Children’s Hospital saw high
numbers of BM, with incidence peaking in 2014 and 2016.45 There
are many cases of BM recorded in Northern China with unknown
causative pathogens, and atypical clinical manifestations; of 148 BM
patients admitted to Beijing Children’s Hospital between 2007 and
2008, the most commonly reported clinical characteristics were fever,
lethargy and convulsion.45 Neurological sequelae commonly asso-
ciated with BM include hearing loss, mental retardation, delayed
language acquisition, visual impairment and behavioral problems.45
A recent study reported that the estimated incidence of BM was
1.84–2.93 cases per 100,000 within the entire population and 6.95–
22.30 for children <5 years from 2006 to 2009, with half of all
patients aged <15 years.46 The causative pathogens identified within
these cases were Nm (35.1%), Hib (12.2%) and Streptococcus
pneumoniae (52.7%), with BM caused by S. pneumoniae most prev-
alent in children <2 years and adults >45 years accounting for 30.8%
and 20.5% of cases, respectively.46 Further, all confirmed cases of Hib
were in children <2 years.46 Similarly, in Hefei, China the esti-
mated incidence of BM was 9.3 cases per 100,000 for children aged
1 month–15 years, and 19.2 cases per 100,000 for children aged 1
month–5 years between 1990 and 1992.47 In the same study, the
predominant causative pathogens of BM observed were Hib, Nm
and S. pneumoniae, which accounted for 51.7%, 38.3% and 8.3% of
cases, respectively.47 Other common BM-causing isolates in China
are coagulase negative Staphylococcus, Enterococcus, Escherichia coli
(E. coli) and Acinetobacter baumannii.48,49
As discussed in the case of Shanghai, China with prophylaxis for
Nm, high levels of antibiotic resistance have also been reported in
cases of BM. From 2010 to 2014, the main causative pathogens
among 507 children with BM in Beijing were identified as S.
pneumoniae (33.2%), E. coli (10.9%), Enterococcus (10.0%) and group
B Streptococcus (8.2%).48 Following penicillin susceptibility testing,
high levels of antibiotic resistance rates were reported, and the total
non-susceptibility rate of S. pneumoniae to penicillin was 47.6%. The
resistance rates of S. pneumoniae isolates to ceftriaxone, cefepime
and ceftazidime antibiotics were 75%, 55.6% and 40%, respectively.48
Further, the five most common BM isolates were coagulase nega-
tive Staphylococcus (58.9%), Micrococcus (5.5%), S. pneumoniae (5.1%),
E. coli (4.8%) and Enterococcus faecium (3.9 %) were reported between
2007 and 2014. S. pneumonia had a 77.7% resistance rate to peni-
cillin and 100% sensitivity rates to vancomycin and E. coli to
piperacillin, tazobactam and meropenem.50
Sentinel surveillance and etiological analysis in Shandong from
2006 to 2012 confirmed 309 cases of BM.51 Of 61 patients with
laboratory-confirmed BM, 32 cases were due to serogroups B, C, W
and unspecified Nm, and 29 cases were due to S. pneumoniae. Up
to 87% of BM cases were successfully treated or had a positive disease
prognosis.51
The continued presence of BM among the Chinese population
is attributed to a number of risk factors, including lack of immu-
nity to specific pathogens, close contact with patients, absence of
breastfeeding among infants aged 2–5 months and crowding. In a
follow-up study of 33 patients with recurrent purulent meningi-
tis, the risk factor responsible for the greatest proportion of cases
was congenital abnormal anatomic structure (75%), followed by
trauma in cephalic or vertebral region or operation (15%), and con-
genital immunodeficiency (9%).52 Further, PCR-based sequencing used
to analyze blood samples taken from 218 child patients with con-
firmed BM and 330 healthy adult controls indicated that
polymorphisms in toll-like receptor 2 and toll-like receptor 9 are
associated with BM severity and poor prognosis in Chinese children.53
The treatment of BM in China depends on the pathogen, disease
severity, complications and antibiotic treatment response. For
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example, antibiotics are discontinued when associated symptoms
are no longer observed, normal temperature has been achieved for >1
week, normal CSF levels are present and protein/glucose and patho-
genic tests are negative. In China, pediatric BM incidence data
indicates that cases attributable to Nm are declining, whereas S.
pneumoniae cases are increasing despite the availability of conju-
gate vaccines. China still faces many challenges in the treatment of
acute BM, such as the notifiable diseases reporting system, etiolo-
gy and surveillance, antibiotic resistance, societal and governmental
awareness and vaccination status.10,54
Importance of conjugate vaccines in the prevention of meningococcal
disease
In 1999, the UK became the first country to implement the me-
ningococcal serogroup C conjugate vaccine into the national
vaccination schedule.55 Unlike polysaccharide vaccines, conjugate
vaccinations have the ability to impart herd protection via the pre-
vention of the acquisition of carriage among the healthy population56
and have been shown to reduce the acquisition of nasopharyngeal
carriage of Hib,57 S. pneumoniae,58 MenC,56 MenA59 and MenY.60 Con-
jugate vaccines are currently available for MenA and MenC, Hib and
Nm. Mono- and multi-valent conjugate vaccines are recommended
in UK national immunization programs for infants, adolescents and
“at risk” groups.
The MenC conjugate vaccine was introduced in the UK as the
primary vaccine for all infants aged 2, 3 and 4 months, and as a single
dose “catch-up” program for all adolescents up to 18 years.55 From
1999 to 2015, the incidence of MD declined significantly. Indeed,
epidemiological surveillance revealed that ≥1 year after primary
infant immunization the efficacy of the MenC vaccine (estimated
as direct protection afforded to vaccinated rather than unvacci-
nated individuals in the same population) significantly declined from
97% to 68%.61 Data from infants who received three doses of the MenC
conjugate vaccine, at ages 2, 3 and 4 months, indicated that serum
bactericidal antibody (SBA) titers significantly increased over three
doses in early infancy, before falling to pre-vaccination levels by 4
years of age.62 Although the MenC conjugate vaccine was priming
for immune memory, the booster response was too slow to prevent
disease, confirming that immunological memory alone was insuf-
ficient to provide long-term disease protection.63 The UK
immunization schedule subsequently evolved in 2006, to include
a booster dose at age 12 months in addition to two primary doses
at ages 3 and 4 months (2 + 1 schedule).64
As antibody levels still rapidly declined following a 2 + 1 dosing
schedule, the immunization schedule was altered to include ado-
lescent vaccination in an effort to maintain the herd protection.55
The effect of both direct and indirect immunization provided a
marked reduction in MD carriage rates in the UK (71% reduction
from 1999 to 2000, further reducing to 81% by 2001 in a cohort of
15,000 immunized teenagers aged 15–19).56 A 67% reduction in the
incidence rate of MenC in an unvaccinated UK cohort demon-
strated an immunoprotective effect of the MenC vaccination program,
and successful herd protection.65
The success of the MenC conjugate vaccine in the UK in reduc-
ing the incidence of MD can be attributed to the combined efficacy
of the vaccine against disease and carriage, and the nature of the
vaccine introduction strategy. Indirect protection is a significant com-
ponent of disease control in the UK. In UK students, the Nm carriage
rate increases dramatically within the first week of university due
to an increase in the number of “high-risk” behaviors, such as at-
tending bars, night clubs and places with overcrowding, and
smoking.66,67 The use of a “catch-up” campaign among adoles-
cents was paramount to the successes of the MenC conjugate vaccine
in reducing the prevalence of the disease in the UK, providing both
direct and indirect protection to immunized and unimmunized in-
dividuals, respectively. The vaccination policy in China is currently
under review, and the introduction of conjugate vaccinations into
the EPI schedule is being considered to increase the proportion of
the population protected against MD.
Outbreak control
Learnings from routine MenB immunization in the UK
Bexsero®, a multicomponent MenB vaccine (4CMenB),68 was in-
troduced into the UK national immunization schedule in 2015 in
infants aged 2, 4 and 12 months. Following the implementation of
this vaccine, the number of recorded cases of MD dropped in the
vaccination eligible cohort and vaccine effectiveness was reported
at 83%.69 While the MenB vaccine does not provide protection against
all strains of MenB, it is estimated to protect against 88% of MenB
strains in the UK and, as such, provide vaccine effectiveness of 94%.
To date, there have been no reported safety concerns associated with
the use of the vaccine. Current published data suggested that the
MenB vaccine does not show a significant effect on the carriage of
MenB; however, surveillance efforts are ongoing to accurately assess
the impact of the vaccine on meningococcal carriage rates.60
Trumenba® is a bivalent MenB vaccine that contains two fHbp
variants.70,71 Trumenba® has been licensed in the USA since 2014,
and is given to adolescents aged 10–25 years; as such, the vaccine
is predominantly used in outbreaks.70 In the European Union (EU),
Trumenba® has been licensed since 2017 for individuals aged >10
years, and it is likely, in the USA, that the vaccine will be used in
outbreak settings.70–72
Conjugate vaccines against serogroups A, C, Y and W are highly
effective in the prevention of MD, especially via the interruption of
the acquisition of carriage.56,59,60 Broad coverage vaccines for
serogroup B disease are now licensed in the USA, EU and else-
where. As MenB is a highly prevalent MD serogroup worldwide, and
incidence rates are increasing in China10 would be advantageous for
there to be a licensed serogroup B vaccine in China that could be
considered for future use in the Chinese National Immunization
Programme.
Learnings from routine MenB immunization in Seine-Maritime,
Northern France
MLST and phenotyping determined that MenB isolates from
Seine-Maritime were B:14:P1.7,16 and cc32; B:14:P1.7,16 ac-
counted for approximately 50% of the total MenB strains observed
in Seine-Maritime, but only 5% of the total MenB cases in France,
indicating varying global and temporal incidence with a specific lo-
calization of this strain in Seine-Maritime. The case fatality rate for
this strain was significantly higher than that of other serogroup B
cases at 19% compared with 8%; as such, urgent action was re-
quired to reduce the spread of MenB.73
Due to similarities in the PorA protein between the B:14:P1.7,16
Seine-Maritime strain and the Norwegian B:15:P1.7,16/ST32 isolate
used to develop the outer membrane vesicles (OMV)-based vaccine,
the MenB vaccine (MenBvac®) developed in Norway, was deter-
mined as effective against the French isolate.74 The vaccine was
therefore able to eradicate the Seine-Maritime strain at a level not
significantly different from that of the original vaccine strain.74
More than 26,014 individuals were identified as eligible for vac-
cination with the MenB vaccine; however, due to a shortage of the
vaccine, individuals aged 1–5 years were initially targeted (as this
age group showed the highest incidence of B:14:P1.7,16 cases).73 In-
dividuals living in Seine-Maritime aged 1–19 years were vaccinated
from June 2006 onwards. The vaccine campaign was halted in 2013,
as the incidence of the strain reverted to pre-vaccination levels. It
was confirmed that the MenB vaccine produced short-lived re-
sponses (showed by a similar percentage of patients with an
SBA titer of ≥4 before and five years after the vaccination).75,76
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Approximately 200 isolates were obtained in a carriage study of vol-
unteers between 1 and 25 years; however, only five had the outbreak
strain (B:14:P1.7,16/ST-32). As the carriage rate is 0.31% among vac-
cinated children versus 2.10% in non-vaccinated children, this
suggested that the vaccine may impact carriage regardless of
serogroup. Subsequently, there were no cases of B:14:P1.7,16 in the
Seine-Maritime between 2014 and 2015 and only one reported case
in 2016; however, the strain is still present in France. Further, since
the outbreak of MenB in Seine-Maritime, France Bexsero® has
become widely available and Trumenba® is expected shortly.
Learnings from routine MenA immunization in Africa
China and Africa differ in many senses; however, both have
regions that are overcrowded. Further, both countries have re-
ported inexplicable similarities in the 10-yearly cycles of MD
epidemics.10,77 The “meningitis belt” of sub-Saharan Africa con-
sists of 26 countries with extremely high prevalence rates of Nm:
from 1986 to 2015, there were approximately 1.3 million cases of
MD, accounting for approximately 80% of the global burden of the
disease. In the “meningitis belt”, epidemics occur periodically every
3–4 years. The high incidence of MD is thought to be due to the
windy sub-Saharan climate, which favors colonization and trans-
mission of Nm in the nasopharynx. Historically, >80% of Nm
outbreaks in the “meningitis belt” were caused by serogroup A com-
pared with serogroups C, W or X.
Licensed in 2009, the monovalent MenA conjugate vaccine
MenAfriVac® initiative was designed to eliminate MenA epidem-
ics from Africa and provide long-term efficacy against the disease
at an affordable price.78 The introduction strategy of the monova-
lent MenA conjugate vaccine was to provide indirect disease
protection via the induction of herd protection by immunizing the
population aged 1–29 years with a 10 μg dose of the vaccine. A 5 μg
dose of the vaccine was then introduced into the EPI in order to
provide direct protection of the new birth cohort. The highest pri-
ority for vaccination was given to countries with the highest
incidence of MenA, and a multi-phase approach was used in order
to target as much of the population as quickly as possible. To date,
over 270 million people have been vaccinated across the majority
of countries in the “meningitis belt” and enhanced surveillance is
in place in order to detect potential outbreaks and monitor the
impact of the MenA vaccine on incidence levels.
The introduction of the MenAfriVac® campaign has successful-
ly reduced the incidence of meningitis and carriage due to Nm
serogroup A; overall, enhanced surveillance indicates a 60% decline
in the incidence of Nm and a 90% decline in MenA.79,80 The mon-
ovalent MenA conjugate vaccine has a number of properties that
contribute to its success. The vaccine is thermostable and can be
kept in a controlled temperature chain at temperatures of less than
40 °C for up to four days. The vaccine is well tolerated, with few
adverse events seen following immunization, and inexpensive at
around $0.50 per dose. Finally, the national campaigns had 95% cov-
erage rates on average; although the vaccination program easily
captured infants, adolescents were less well covered and as such,
“mop-up” campaigns were launched in countries with low cover-
age rates.
MenAfriVac® has been progressively introduced into the im-
munization schedules of countries in the “meningitis belt”; however,
there is much work yet to be done. The monovalent MenA conju-
gate vaccine is not yet implemented into routine immunization
schedules in all countries in the “meningitis belt”. Further, there
remains a continued risk of a meningitis outbreak due to an alter-
native serogroup; serogroups X, W and C are still present in Africa
and the re-emergence of MenC is a growing concern, particularly
in Niger and Nigeria. The ideal vaccine would be a five-valent con-
jugate vaccine that protects against serogroups A, C, X, Y, and W and
that is affordable, thermostable and well tolerated.
The MenA vaccine reduced carriage rates and invasive disease
inducing herd protection and direct protection, respectively. The key
characteristics responsible for the success of the vaccine initiative
were its continued efficacy outside of the cold chain, the develop-
ment of tailored doses for campaign or routine settings and the low
manufacturing costs. It is tempting to speculate that a similar ap-
proach could be adopted in China for the production of conjugate
vaccines against MenA, MenC and MenA/C plus Hib to improve cost-
effectiveness and increase the likelihood of introduction into the EPI.
Outbreak preparedness
Key WHO recommendations for the outbreak response and pre-
paredness are relevant to all countries, including China, and as such,
universal standard operating procedures should be defined and
implemented globally. Adequate MD surveillance is paramount to
the detection of disease outbreak and aids with a timely and ef-
fective response. During an MD outbreak, the correct identification
of the causative serogroup is important to identify the most ap-
propriate antibiotic prophylaxis if needed. Further, epidemiological
data are needed to estimate disease burden, geographical location
and to identify “at-risk” populations. Once the vaccination re-
sponse has occurred, epidemiological data collected via surveillance
networks are required to determine vaccine effectiveness.
Although surveillance in China should cover the whole country,
provinces may have different surveillance objectives and there-
fore sentinel surveillance may be sufficient. The aim of the invasive
Bacterial Vaccine-Preventable Disease (IBVPD) surveillance network
is to assess the impact of vaccination. A laboratory component is
essential (e.g. culturing or PCR) to disease surveillance, as rapid iden-
tification of the serogroup is critical in determining the response
needed at a local and national level. Lumbar puncture for CSF is the
most accurate way to confirm meningitis; however, future diag-
nostic methods may include the collection of other fluids (e.g. blood),
as in many regions lumbar puncture kits may not be available, as
is true in Africa. Furthermore, laboratory capacities vary at a local,
provincial and national level and various aspects of surveillance
require standardized, country-specific protocols in order for the pro-
vision of timely disease data to support case management and
reactive vaccination and treatment strategies. Once in place, there
is a need to define and continuously monitor surveillance indica-
tors to ensure optimal quality. The use of a weekly national bulletin
in which all laboratory data are provided to all provinces to monitor
epidemiology, and a support network within and among neighbor-
ing countries may be beneficial in disease surveillance. This approach
has worked well in Africa following the introduction of MenAfriVac®,
and a similar approach may be effective in China.
The definitions for alert and epidemic thresholds will vary among
countries and are directly related to the level of disease burden; for
example, in Africa 3 per 100,000 persons per week trigger “alert”
actions. Similar to Africa, China is hugely populated and this ap-
proach may prove effective. For example, an epidemic threshold level
could be defined for each Chinese sub-county, at which neighbor-
ing counties would be alerted to a rising incidence of MD. This would
lead to the reactive vaccination of the target population in re-
sponse to epidemic threshold, which when complete would in turn
lead to the cessation of the alert. It is tempting to speculate that
this would be a very effective method in the prevention of future
epidemics in China.
The most important aspect of reactive protocols for vaccina-
tion and antibiotic prophylaxis is speed. In Africa, vaccination should
occur within 4 weeks after having reached the threshold, and similar
time constraints could be developed in China. Polysaccharide vac-
cines are usually given due to a lower cost compared with conjugate
vaccines; however, global supply is limited. Antibiotics should be
given early (within 72 hours) in order to prevent death and com-
plications; although, the antibiotic used is subject to antibiotic
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resistance. The development of rapid bedside diagnostic tests may
be useful for the global community to enable a better response to
meningitis outbreaks and several prototypes are currently in
development.81,82
Standardized protocol for procedures to outline actions during
an MD epidemic are needed within and among countries (includ-
ing defined alert and epidemic thresholds), which emphasize the
importance of disease surveillance. These could be developed for
provinces across China in order to standardize outbreak response
and disease control.
Conclusions and key recommendations
Based on the surveillance, diagnosis and confirmation data pre-
sented at this GMI meeting, it is clear that meningococcal
epidemiology is changing in China with the decline of serogroup
A disease, emergence of new clones of serogroup B and C, and as a
consequence of the international spread, an increase in serogroup
W cc11.16,26–29 As MenB is responsible for an increasing number of
MD cases in China, an effective vaccination strategy should be in
place should an outbreak occur; this further emphasizes the im-
portance of standardized laboratory procedures across China. Indeed,
there is a need for improved disease surveillance and standard-
ized laboratory techniques across and within provinces to ensure
optimal epidemiological monitoring. Further, incidence data relat-
ing to pediatric BM in China indicates that Nm cases are declining,
whereas S. pneumoniae cases are increasing, despite the availabil-
ity of conjugate vaccines48; therefore, new vaccination strategies may
be required including the use of conjugate vaccines and a MenB
vaccine to reduce the carriage and induce herd protection acknowl-
edging important lessons from the prior use in the control of MD
outbreaks.
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